<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094809</url>
  </required_header>
  <id_info>
    <org_study_id>20020715</org_study_id>
    <nct_id>NCT00094809</nct_id>
    <nct_alias>NCT00119327</nct_alias>
  </id_info>
  <brief_title>Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer</brief_title>
  <official_title>Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the safety and effectiveness of
      pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy
      regimens (FOIL, FOLFOX or FOLFIRI) in patients with locally advanced or metastatic colorectal
      cancer. This study is considered to be &quot;investigational&quot; because the time between receiving
      pegfilgrastim and the next cycle of chemotherapy is only 11 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3 or 4 Neutropenia</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt; 1 x 10^9/L, in any of the first four cycles of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 4 Neutropenia</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt;0.5 x 10^9/L, in any of the first four cycles of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Delay or Reduction Due to Neutropenia</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Dose delay or reduction in chemotherapy doses due to neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Delay or Reduction for Any Reason</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Febrile Neutropenia</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC &lt; 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Due to a Neutropenia-Related Event</measure>
    <time_frame>First 4 cycles of neutropenia (8 weeks)</time_frame>
    <description>Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 24 months after first four cycles of treatment</time_frame>
    <description>Kaplan-Meier estimate of the median time to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 24 months after first four cycles of treatment</time_frame>
    <description>Death from any cause through the end of the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Use Due to Febrile Neutropenia</measure>
    <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
    <description>Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mg pegfilgrastim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic colorectal adenocarcinoma not curable by surgery or
             amenable to radiation therapy with curative intent.

          -  Histologically or cytologically documented locally advanced or metastatic colorectal
             cancer. The site of the primary lesion must be or has been confirmed endoscopically,
             radiologically, or surgically to be or has been in the large bowel.

          -  Measurable or evaluable disease.

          -  ECOG performance status 0, 1 or 2

          -  Life expectancy ≥ 12 weeks

          -  All of the following: (1) ≥ 4 weeks must have elapsed from the time of major surgery
             and subjects must have recovered from the effects (e.g., laparotomy); (2) ≥ 2 weeks
             must have elapsed from the time of minor surgery and subjects must have recovered from
             the operation (insertion of a vascular access device is not considered major or minor
             surgery); (3) ≥ 4 weeks must have elapsed from the time of major radiotherapy (e.g.,
             chest or bone palliative radiation therapy).

          -  Subjects may have received prior adjuvant therapy and one prior chemotherapy regimen
             for metastatic disease providing 30 days has elapsed from last chemotherapy dose.

          -  Subject must have recovered from prior chemotherapy complications and in the opinion
             of the investigator, the subjects current status does not place the subject at risk
             for entry into the trial.

          -  Subjects with prior exposure to both oxaliplatin and irinotecan will not be eligible
             to participate in this study. However, if subject received prior therapy with
             oxaliplatin, they will be eligible to receive the FOLFIRI regimen. If subject received
             prior therapy with irinotecan, they will be eligible to receive the FOLFOX regimen.

          -  Age ≥ 18 years

          -  Absolute neutrophil count ≥ 1.5 x 109/L

          -  Platelet count ≥100 x 109/L

          -  Hemoglobin ≥ 9.0 g/dL (subjects may be receive a red blood cell transfusion to achieve
             this requirement)

          -  Creatinine ≤ 1.5 x UNL

          -  Total bilirubin ≤ 1.5 mg/dL (≤ 25.65 μmol/L), regardless of whether subjects have
             liver involvement secondary to tumor

          -  Aspartate aminotransferase ≤ 5 x UNL

          -  Alkaline phosphatase ≤ 5 x UNL

          -  Informed consent to participate on the study.

        Exclusion Criteria:

          -  Standard chemoradiation as adjuvant treatment for colorectal cancer will be allowed,
             but prior radiotherapy to &gt;15% of bone marrow or outside of standard adjuvant
             colorectal cancer chemoradiation is not allowed.

          -  Known central nervous system metastases or carcinomatous meningitis.

          -  Predisposing colonic or small bowel disorders in which the symptoms are uncontrolled
             as indicated by baseline pattern of &gt;3 loose stools daily in subjects without a
             colostomy or ileostomy. Subjects with a colostomy or ileostomy may be entered at the
             Investigator's discretion.

          -  Pleural effusion or ascites, which cause respiratory compromise (≥Grade 2 dyspnea).

          -  Concurrent use of other investigational agents.

          -  No active infection requiring the start of systemic (intravenous or oral)
             anti-infective (antibiotic, antifungal, antiviral) within 72 hours of the
             administration of the first cycle of study chemotherapy.

          -  Symptomatic sensory peripheral neuropathy.

          -  The following conditions: Uncontrolled high blood pressure; unstable angina;
             symptomatic congestive heart failure; myocardial infarction ≤ 6 months prior to
             randomization; serious uncontrolled cardiac arrhythmia; New York Heart Association
             classification III or IV.

          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, adequately treated noninvasive carcinomas, or other cancer from which the
             patient has been disease-free for at least five years.

          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.

          -  Medical or psychiatric conditions which, in the opinion of the Investigator, make
             participation in an investigational trial of this nature a poor risk.

          -  Known sensitivity to E. coli derived products (e.g., Filgrastim, HUMULIN® insulin,
             L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A) or known sensitivity to any of
             the products to be administered during dosing.

          -  Subject is currently enrolled or has not yet completed at least 30 days since ending
             other investigational device or drug trial(s) or is receiving other investigational
             agent(s).

          -  Subject of child-bearing potential is evidently pregnant (e.g., positive HCG test) or
             is breast feeding.

          -  Subject is not using adequate contraceptive precautions.

          -  Subject will not be available for follow-up assessment.

          -  Concerns for subject's compliance with the protocol procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013.</citation>
    <PMID>20378503</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2004</study_first_submitted>
  <study_first_submitted_qc>October 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2004</study_first_posted>
  <results_first_submitted>December 16, 2010</results_first_submitted>
  <results_first_submitted_qc>December 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2011</results_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neulasta®</keyword>
  <keyword>pegfilgrastim</keyword>
  <keyword>Advanced</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 12 February 2003 through 13 January 2006</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegfilgrastim (Neulasta)</title>
          <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Properly Consented; Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed All 4 Cycles of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74">Subjects who completed treatment and Long term follow up (LTFU)</participants>
                <participants group_id="P2" count="61">Subjects who completed treatment and LTFU</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Informed consent signed after treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug not received</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegfilgrastim (Neulasta)</title>
          <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="12.26"/>
                    <measurement group_id="B2" value="62.9" spread="13.21"/>
                    <measurement group_id="B3" value="62.7" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chemotherapy Regimen</title>
          <description>FOIL = 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin; FOLFOX = 5-fluorouracil, oxaliplatin, and leucovorin; FOLFIRI = 5-fluorouracil, irinotecan, and leucovorin</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>FOIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLFOX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLFIRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Grade 3 or 4 Neutropenia</title>
        <description>Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt; 1 x 10^9/L, in any of the first four cycles of treatment</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3 or 4 Neutropenia</title>
          <description>Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt; 1 x 10^9/L, in any of the first four cycles of treatment</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>Common odds ratio of the pegfilgrastim group compared to the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Delay or Reduction Due to Neutropenia</title>
        <description>Dose delay or reduction in chemotherapy doses due to neutropenia</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Delay or Reduction Due to Neutropenia</title>
          <description>Dose delay or reduction in chemotherapy doses due to neutropenia</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.2</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
            <estimate_desc>Treatment difference in percentage of participants (pegfilgrastim group - placebo group)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Delay or Reduction for Any Reason</title>
        <description>Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Delay or Reduction for Any Reason</title>
          <description>Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0646</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-23.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Treatment difference in percentage of participants (pegfilgrastim group - placebo group)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Febrile Neutropenia</title>
        <description>Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC &lt; 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Febrile Neutropenia</title>
          <description>Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC &lt; 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Common odds ratio of pegfilgrastim group compared to placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalization Due to a Neutropenia-Related Event</title>
        <description>Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment</description>
        <time_frame>First 4 cycles of neutropenia (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization Due to a Neutropenia-Related Event</title>
          <description>Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5514</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
            <estimate_desc>Common odds ratio for pegfilgrastim group compared to placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>Kaplan-Meier estimate of the median time to disease progression or death</description>
        <time_frame>Up to 24 months after first four cycles of treatment</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>Kaplan-Meier estimate of the median time to disease progression or death</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318" lower_limit="258" upper_limit="387"/>
                    <measurement group_id="O2" value="322" lower_limit="268" upper_limit="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response</title>
        <description>Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response</title>
          <description>Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5434</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.8</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
            <estimate_desc>Treatment difference (pegfilgrastim group - placebo group) in the percentage of participants with a complete or partial response</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Death from any cause through the end of the follow-up period</description>
        <time_frame>Up to 24 months after first four cycles of treatment</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Death from any cause through the end of the follow-up period</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment difference</param_type>
            <param_value>-12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.1</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Kaplan-Meier estimates of the difference in percent mortality for the pegfilgrastim group - placebo group. Median survival time was not reached for the pegfilgrastim group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibiotic Use Due to Febrile Neutropenia</title>
        <description>Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Use Due to Febrile Neutropenia</title>
          <description>Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0457</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Common odds ratio for pegfilgrastim group compared to placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 4 Neutropenia</title>
        <description>Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt;0.5 x 10^9/L, in any of the first four cycles of treatment</description>
        <time_frame>First 4 cycles of treatment (8 weeks)</time_frame>
        <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Pegfilgrastim (Neulasta)</title>
            <description>Pegfilgrastim 6 mg by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by subcutaneous injection once every 2 weeks at least 24 hours after 5-fluorouracil infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 4 Neutropenia</title>
          <description>Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) &lt;0.5 x 10^9/L, in any of the first four cycles of treatment</description>
          <population>Primary Analysis Set, composed of all participants who received study drug and who signed an informed consent before any invasive procedures</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3792</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Adjusted for chemotherapy regimen</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>Common odds ratio of the pegfilgrastim group compared to the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment period and including 30 days after last dose of IP</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
One subject randomized to pegfilgrastim arm was not summarized in the safety analysis set due to improper informed consent.
Another subject who was randomized to placebo arm but received pegfilgrastim and was summarized in pegfilgrastim arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Pegfilgrastim</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Colon gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Intestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antimicrobial susceptibility test resistant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Prothrombin level increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

